Αρχική World News Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to...

Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to Improve Patient Outcome Following Immune Checkpoint Inhibitor Therapy

Patients receiving immune checkpoint inhibitor (ICI) treatment who developed a rheumatic immune-related adverse event (irAE) displayed symptoms that resembled classical rheumatic and musculoskeletal diseases (RMDs), but seldom fulfilled their classification criteria mainly due to dissimilar laboratory characteristics. These and other findings were presented by Dr Karolina Benesova of the Department of Medicine V, Haematology, Oncology and Rheumatology, University Hospital in Heidelberg, Germany at the ESMO Virtual Congress 2020.

Dr Benesova discussed the occurrence and characteristics of rheumatic irAEs which have been associated with better tumour response following treatment with ICIs. She initiated the open-end TRheuMa registry, a prospective long-term observational study, to obtain real world data on patient characteristics and to determine the optimal clinical management of rheumatic irAEs. This study involves a patient cohort coping with rheumatic side effects of cancer therapies and is part of the large MalheuR project initiated in July 2018 at the University Hospital Heidelberg to explore interrelations of malignancies and RMDs.

TRheuMa registry provides real world data on rheumatic irAEs and patients outcome

By now, 65 patients have been recruited with a rheumatic irAE under ICI treatment; of these, 30 patients were treated with nivolumab, 33 with pembrolizumab, 12 patients with ipilimumab, 6 patients received treatment with a PD-L1 inhibitor and 10 patients received treatment with a combination of ICI agents.

The patient population comprised 47.7% of patients with NSCLC and 40.0% of patients with melanoma. In local cohorts of patients receiving ICI, 4.1% of NSCLC (n total=888) and 13.3% of melanoma (n total=195) developed a rheumatic irAE.

Flares of a pre-existing RMD were experienced by 15.4% of study patients and 9.2% of patients had an initial manifestation of a classical RMD. The de novo rheumatic irAEs primarily resembled the phenotypes of rheumatoid arthritis in 24.1% of patients, polymyalgia rheumatica in 16.7%, or spondyloarthritis in 46.3% of patients.

However, the de novo rheumatic irAEs presented with different laboratory findings, including mostly negative or unspecific autoantibodies and elevated CRP-levels in 77.4% of patients. On the basis of the clinical manifestations, CRP levels were often significantly higher than would be expected in classical RMDs and showed values >50 mg/L in 30.6% of patients.

Furthermore, 96.1% of the patients had signs of inflammation upon ultrasound examination with often symmetrical synovialitis and/or tenosynovialitis in the majority of cases.

According to a severity-based treatment algorithm developed by the investigators, therapy with ≤10 mg prednisone with/without NSAID was sufficient to resolve the irAEs in 53.8% of patients, but 15.4% required add-on cs-/bDMARD therapy. Ten (15.4%) patients discontinued ICI treatment temporarily or permanently due to the rheumatic irAE.


Severity-based treatment algorithm of rheumatic irAEs: Interdisciplinarily developed treatment algorithm based on subtypes and severity of rheumatic immune-related adverse events (irAE) due to immune checkpoint inhibitors (ICI). § At level II, consultation of a rheumatologist should be considered. At level III and above, timely consultation of a rheumatologist is strongly recommended. * Add-on therapy with cs/bDMARDs (conventional synthetic (e. g. methotrexate) or biologic (e. g. TNFα-inhibitors) disease-modifying antirheumatic drugs) can take up to 8-12 weeks until onset of therapeutic response. Supportive therapy includes non-NSAID analgetics, physio- and ergotherapy.

© Karolina Benesova: Benesova K, et al. ESMO Open 2019, Nephrologe & Z Rheum 2020.

Interestingly, 48.0% of patients with a rheumatic irAE in this study compared with 4% of patients without an irAE in a historical control achieved complete remission of melanoma as best response and 45.8% of irAE-patients showed longstanding complete remission also as current outcome. In NSCLC patients, 69.0% reached a partial remission as best possible response.


According to the authors, these prospective real world data from the TRheuMa registry show that rheumatic irAEs mostly resemble classical RMDs with some distinct characteristics. Their clinical management strategy was effective and underlined a patient centred and interdisciplinary approach. Research on this immunological intersection between malignancies and RMDs offers the opportunity for better patient centred care and scientific progress.

The investigators future research agenda includes long-term observation of rheumatic irAEs and correlation with specific oncological outcomes.

Dr. Benesova is now supported by the medical faculty of the University of Heidelberg, Germany to advance the MalheuR project.


1809O – Benesova K, Diekmann L, Lorenz H-M, et al. TRheuMa registry provides real world data on rheumatic immune-related adverse events. ESMO Virtual Congress 2020.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

Easy Meals at Home

Our theme this week is delicious, easy to make, at home meals. These recipes minimize your cook time and maximize your food enjoyment. Ingredients 8...

This Saturday: National Prescription Drug Take-Back Day

Have you taken a look at your medicine cabinet lately? Aside from cotton swabs, mouthwash and makeup remover, are there old, outdated prescription drugs...

How People With Cancer Can Benefit From Online Therapy

Tanya J. Peterson, MS, is credentialed with the National Board of Certified Counselors. She is a regular contributor to the mental health website, Choosing...

EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

New Treatment Helps Survivors Regain Sensation After Breast Cancer

When NBC’s Kristen Dahlgren was diagnosed with breast cancer, she didn’t think much about the lack of sensation that her mastectomy would likely leave...